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Abstract
Background: Normal upper endoscopy may be a marker of ischemic heart disease in patients
with unexplained chest/epigastric pain.
Methods: We examined the 10-year risk of ischemic heart disease and mortality in a cohort of
386 Danish patients with chest/epigastric pain, normal upper endoscopy, and no prior hospital
discharge diagnosis of ischemic heart disease (defined as patients with unexplained chest/epigastric
pain), compared with 3,793 population controls matched by age, gender, and residence. Outcome
data were obtained from population-based health registries. Cox regression analysis was used to
estimate the relative risk of hospitalization for ischemic heart disease and the adjusted mortality
rate ratio (MRR).
Results: The 10-year relative risk of hospitalization for ischemic heart disease following a normal
upper endoscopy among patients with unexplained chest/epigastric pain was 1.6 (95% CI, 1.1–2.2),
compared with controls. The 10-year MRR was 1.1 (95% CI, 0.9–1.5). Within the first year after
the upper endoscopy the MRR was 2.4 (95% CI, 1.3–4.5). The cause-specific MRR among patients
with unexplained chest/epigastric pain compared with controls was up to threefold higher for
deaths related to alcohol dependence, pneumonia, and lung cancer.
Conclusion: Unexplained chest/epigastric pain in patients with normal endoscopy is a strong
marker for ischemic heart disease and increased mortality.
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Pain originating in the upper and lower gastrointestinal
tract is complex and common in the general population
[1,2]. Unexplained chest/epigastric pain (UCEP) may
reflect either undiagnosed thoracic or abdominal organic
diseases or upper functional gastrointestinal disorders
(FGIDs) [3,4]. Patients with chest and epigastric pain are
often referred to gastroenterologists for evaluation of pos-
sible organic or functional causes [5,6].
In two recent cohort studies, we suggested that UCEP
might reflect early symptoms of gastrointestinal cancer
[7], pancreatitis, and gallstone [8]. Whether UCEP may
also be a marker of increased risk of death or ischemic
heart disease (IHD) remains unclear. The evidence prima-
rily consists of small case series [9-12] and a few follow-
up studies with inconsistent results and significant limita-
tions [13-16]. Half of the studies failed to include a con-
trol group, and UCEP was defined in most cases on the
basis of only chest pain and a normal coronary angiogra-
phy [9-12]. More importantly, none of the studies
excluded patients whose pain could have been caused by
an underlying gastrointestinal disease, such as peptic ulcer
or gastro-esophageal reflux disease (GERD) [9-16]. Thus,
it is uncertain whether all study subjects had truly unex-
plained pain.
We conducted a follow-up study in Denmark to examine
hospitalization for IHD, all-cause mortality, and cause-
specific mortality in UCEP patients compared with popu-
lation controls (using the same study population of
patients as in our two previous prognostic studies on
UCEP patients [7,8]).
Methods
Study design and population
This 10-year follow-up study was conducted at the Aarhus
University Hospital in Aarhus County, Denmark. The
county has a population of approximately 650,000 (12%
of the Danish population). The Aarhus University Hospi-
tal has the county's largest departments of gastroenterol-
ogy and surgery, and most upper endoscopies in the
county are performed there. We obtained data on all
patients who underwent upper endoscopy at the hospital
between January 1, 1992 and December 31, 1993, with a
10-year follow-up period extending until December 31,
2003.
Linkage between registries
Records in all registries used in this study contain the Dan-
ish Civil Registration System's unique 10-digit civil regis-
tration number, which is assigned to all Danish citizens at
birth [17]. Use of the civil registration number allows
valid linkage between registries.
UCEP patients
The Aarhus University Hospital Endoscopy Registry con-
tains both paper files and electronic medical records for
all patients who underwent upper endoscopy since 1976.
Since 1977 the electronic record has been maintained by
the Hospital Administrative Patient Registry. Each record
includes information on the patient's civil registration
number, dates of admission and discharge, date and type
of procedures performed, and diagnoses coded by physi-
cians according to the International Classification of Dis-
eases (ICD). ICD-8 codes were used in 1977–1993, and
ICD-10 codes thereafter (ICD-9 was never used in Den-
mark) [18]. Hard-copy medical records consist of referral
notes (nearly 90% of the patients are referred from general
practitioners as outpatients) and endoscopy records writ-
ten by the physicians who performed the procedures. The
latter include information on presenting symptoms (indi-
cation for the procedure), diagnoses made during the
endoscopy, biopsies taken, and description of subsequent
pathological findings. This information is both standard-
ized by means of a checklist and described in free text.
General practitioners' referral notes are not standardized
and mainly include information on the patients' history
and symptoms. We ascertained patients' symptoms both
from the endoscopy records and from the referral notes,
and for the majority of patients the descriptions of the
presenting symptoms from the two sources were in agree-
ment. One of the study physicians (EMM) coded and
entered data from the hard-copy medical records into an
electronic research database.
The physicians who performed the upper endoscopy did
not take part in the evaluation of the data of the study,
selection of patients for the study, study analyses, or inter-
pretation of the results in the study.
During the recruitment period we identified 1,799
patients with a first-time normal upper endoscopy. These
patients were classified into four groups according to their
symptoms: (a) only chest/epigastric pain, (b) reflux-like
symptoms (e.g., heartburn and/or acid reflux), (c) neither
chest/epigastric pain nor reflux-like symptoms, and (d)
both chest/epigastric pain and reflux-like symptoms. The
subcohort of interest was comprised of the first group:
410 (23%) patients with only chest/epigastric pain and a
first-time normal upper endoscopy. Thus, we excluded
patients with symptoms such as specified/unspecified
dyspepsia, heartburn and/or acid reflux or with other
symptoms listed in the endoscopy record and in the refer-
ral note. Our study subcohort of patients with only chest/
epigastric pain and a first-time normal upper endoscopy
was defined and chosen a priori [7,8].
Through linkage to the nationwide Danish Hospital Dis-
charge Registry (HDR), we identified patients with dis-Page 2 of 9
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(myocardial infarction, angina, and/or heart failure [19])
prior to the date of upper endoscopy, coded according to
the ICD diagnoses in Appendix 1. The HDR, established
in 1977, electronically tracks all non-psychiatric hospital-
izations throughout Denmark, including dates of admis-
sion and discharge, procedures performed, and up to 20
discharge diagnoses coded by medical doctors at the time
of discharge. Data also on out-patients were included
from 1995. We excluded 24 patients with a discharge diag-
nosis of IHD prior to the date of upper endoscopy. The
remaining 386 patients comprised the study cohort of
UCEP patients, who may resemble patients with upper
FGIDs [20,21]. The study cohort was identical to the study
cohort used in two recently published studies on other
prognostic outcomes among UCEP patients [7,8].
Population controls
For each UCEP patient, controls residing in Aarhus
County were identified from the Civil Registration System
and matched by age and gender (N = 4,100). The controls
were selected on the date of the corresponding patient's
first-time normal upper endoscopy (the index date). Ten
controls per UCEP patient were randomly chosen to
achieve statistical precision [22]. On the basis of informa-
tion from HDR, 67 controls with discharge diagnoses of
IHD prior to the index date were excluded. The remaining
3,793 controls were included in the analyses [7,8].
Risk of IHD and mortality
Data on hospitalizations for IHD (defined as a discharge
diagnosis of myocardial infarction, angina and/or heart
failure) during the 10 years of follow up were obtained
from the HDR. Mortality was ascertained from the Civil
Registration System, which tracks Danish citizens' births,
deaths, and migrations. In addition, death certificates,
available from the Danish Causes of Deaths Registry, pro-
vided information on cause-specific mortality up to
December 31, 2003. Since 1970, death certificates have
included information on cause and manner of death (nat-
ural death, accident, suicide, or unknown) for 100% of
deceased Danish residents. Because few patients and con-
trols died of unnatural causes, we did not consider man-
ner of death in our analyses.
In our cohort of UCEP patients, we focused on the seven
most common causes of deaths occurring after the date of
normal upper endoscopy: IHD, pneumonia, stroke, arte-
riosclerosis (in the absence of IHD or stroke), lung cancer,
alcohol dependence, and chronic obstructive pulmonary
disease.
Confounding factors
HDR data were used to compute a comorbidity index
score – the Charlson Index [23,24] – for each UCEP
patient and control [7,8]. The Charlson Index, covering 19
major disease categories weighted according to their prog-
nostic impact on patient survival, has been adapted for
use with hospital discharge registry data. We computed
the Index based on diagnoses recorded during all previous
hospitalizations since 1977. We used discharge diagnoses
of alcohol- and smoking-related diseases as proxies for
alcohol abuse and tobacco smoking (ICD codes provided
in Appendix 1) [7,8]. Alcohol- and smoking-related diag-
noses were excluded from the Index to reduce the risk of
residual confounding from these diseases. Three index
levels were defined to capture increasing degrees of
comorbidity: no comorbidity (Charlson Index 0), comor-
bidity level 1 (Charlson Index 1–2), and comorbidity
level 2 (Charlson Index > 2) [7,8].
Statistical analysis
Demographic and clinical variables such as gender, age,
presence of alcohol- and smoking-related diseases, level
of comorbidity, subsequent discharge diagnosis of IHD,
overall mortality, and cause-specific mortality were pre-
sented as proportions or means, as appropriate.
Follow up began on the date of normal upper endoscopy
or the corresponding index date for controls, and ended
on the date of initial diagnosis of IHD, the date of death,
the date of emigration, or at the end of the study period
on December 31, 2003, whichever came first.
We constructed Kaplan-Meier survival curves and used life
table techniques to estimate the risk of hospitalization for
IHD and death and to summarize risk over time [7,8]. Cox
regression was used to calculate the incidence rate ratio as
an estimate of the relative risk and associated 95% confi-
dence interval (CI) of hospitalization for IHD among
UCEP patients compared to that for controls, while
adjusting for alcohol- and smoking-related diseases and
level of comorbidity [7,8]. Cox regression was also used to
estimate the mortality rate ratio (MRR) and associated
95% CI for UCEP patients, relative to controls, while
adjusting for alcohol- and smoking-related diseases and
level of comorbidity. Similarly, Cox regression was used
to estimate the MRR for cause-specific deaths. All-cause
MRRs also were calculated after <1 year, 1–2 years, 3–4
years, and ≥ 5 years of follow up. For pneumonia, cause-
specific MRRs were estimated for the following time peri-
ods: within <7 days, 7–31 days, and ≥31 days after the
index date.
Separate analyses were performed for each type of IHD
(myocardial infarction, angina, and heart failure) and
stratified by time elapsed since the index date (<1 year, 1–
2 years, 3–4 years, and ≥ 5 years).Page 3 of 9
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time periods were assessed graphically and found to be
adequate. Analyses were performed using STATA version
9.1 SE (StataCorp, College Station, Texas, USA). The study
was approved by the Danish Data Protection Agency (#
2001-41-1590).
Results
Table 1 presents selected characteristics of the UCEP
patients and the matched population controls. Compared
with the population controls, UCEP patients had a higher
prevalence of subsequent hospitalization for IHD (11%
vs. 6%), were more likely to have comorbidity scores in
Charlson Index category 1–2 (12% vs. 7%), and more
likely to have alcohol-related diseases (8% vs. 2%). There
was a slight difference between the two groups in ten-year
all-cause mortality (16% of UCEP patients vs. 13% of con-
trols). Except for deaths from alcohol dependence (1% vs.
0.1%) and pneumonia (3% vs. 1%), we found no differ-
ence in proportions of cause-specific deaths between the
two groups.
Risk of hospitalization for IHD
Compared with population controls, the crude relative
risk of hospitalization for IHD among UCEP patients was
1.7 (95% CI, 1.2–2.4) (Table 2). Adjustment for alcohol-
and smoking-related diseases and for level of comorbidity
did not change the estimate. The relative risk of hospitali-
zation for IHD within <1 year, 1–2 years, 3–4 years, and ≥
5 years following upper endoscopy remained consistently
elevated (Table 2). By type of IHD, the adjusted relative
risk was 1.4 (95% CI, 0.8–2.4) for myocardial infarction,
1.9 (95% CI, 1.2–3.0) for angina, and 1.7 (95% CI, 1.0–
2.9) for heart failure. The adjusted relative risk for angina
and heart failure was highest in the first and the second
years following upper endoscopy [4.6 (95% CI, 1.1–18.4)
Table 1: Characteristics of patients with unexplained chest/epigastric pain (UCEP) and matched population controls.
UCEP patients* 
(N = 386)
Population controls** 
(N = 3,793)
Age, n (%)
≤ 39 years 155 (40) 1,553 (41)
40–56 years 114 (30) 1,100 (29)
≥ 57 years 117 (30) 1,140 (30)
Mean age (years) 46.4 46.1
Median age (years) 44 44
Gender, n (%)
Female 222 (58) 2,195 (58)
Male 164 (42) 1,598 (42)
Comorbidity level, n (%)†
No comorbidity 337 (87) 3,473 (92)
Comorbidity level 1–2 45 (12) 286 (7)
Comorbidity level > 2 4 (1) 34 (1)
Discharge diagnoses, n (%)
Alcohol-related diseases 29 (8) 79 (2)
Smoking-related diseases 19 (5) 133 (4)
Patients who developed ischemic
heart disease, n (%)
39 (11) 241 (6)
10-year risk of ischemic heart disease, % 11 6
Deaths, total, n (%) 62 (16) 508 (13)
Death from ischemic heart disease# 8 (2) 76 (2)
Death from stroke 4 (1) 34 (1)
Death from arteriosclerosis
(not ischemic heart disease, not stroke)
4 (1) 51 (1)
Death from pneumonia 12 (3) 41 (1)
Death from lung cancer 5 (1) 27 (1)
Death from alcohol dependence 3 (1) 5 (0.1)
Death from chronic obstructive
pulmonary disease
3 (1) 38 (1)
Death from other causes 21 (5) 217 (6)
10-year mortality, % 16 13
*Normal upper endoscopy and no discharge diagnoses of ischemic heart disease before study entry.
** No discharge diagnoses of ischemic heart disease before study entry.
† No comorbidity (Charlson Index 0), comorbidity level 1 (Charlson Index 1–2). and comorbidity. level 2 (Charlson Index > 2).
# Myocardial infarction, angina, and/or heart failure.Page 4 of 9
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infarction, the relative risk was the highest ≥ 5 years fol-
lowing upper endoscopy [2.0 (95% CI, 0.9–4.3)].
Mortality
Survival curves for UCEP patients and controls are shown
in Figure 1 [see additional file 1]. The crude overall MRR
was 1.2 (95% CI, 1.0–1.6) (Table 3). The estimate
remained unchanged after adjustment for alcohol- and
smoking-related diseases and level of comorbidity. The
adjusted overall MRRs for UCEP patients within <1 year
and 1–2 years after upper endoscopy were 2.4 (95% CI,
1.3–4.5) and 1.7 (95% CI, 0.8–3.9), respectively (Table
3). Thereafter, mortality among UCEP patients was com-
parable to that of controls (Table 3).
Adjusted cause-specific MRRs are shown in Table 3. Ele-
vated mortality was found for death from alcohol depend-
ence [MRR, 1.5 (95% CI, 0.3–8.2)], pneumonia [MRR, 2.7
(95% CI, 1.4–5.2)], and lung cancer [MRR, 1.7 (95% CI,
0.6–4.4)]. Except for one case, all pneumonia deaths
occurred more than 31 days after the upper endoscopy
date. We found no indication of increased mortality due
to IHD [MRR, 1.1 (95% CI, 0.5–2.2)].
Discussion
The ten-year risk of hospitalization for IHD among UCEP
patients was increased 1.6-fold compared with controls.
The highest increase in risk was observed within the first
two years following the upper endoscopy, but the risk
remained elevated even after five years. All-cause mortal-
ity for UCEP patients was 16% over ten years, 1.1 times
higher than the all-cause mortality in the general popula-
tion. In the first year after the upper endoscopy, all-cause
mortality among UCEP patients was nearly 2.5-fold
higher than that of controls, but the difference faded away
with time. The increased mortality among UCEP patients
stemmed from alcohol dependence, pneumonia, and
lung cancer, but not IHD.
The main strengths of our study are its relatively large size,
a well-defined patient sample drawn from a universal-
access health care system, and complete follow-up over
ten years. In Denmark, nearly all patients with IHD are
hospitalized during the cause of the disease (by admission
to hospital either directly or through out-patient clinics),
and this ensured us to registry virtually all IHD diagnoses
among our cohort members. Data used to assess out-
comes and potential confounders were obtained from
routinely recorded discharge diagnoses and causes of
death. While their quality may be variable, the positive
predictive value of heart-related discharge diagnoses has
been reported to be high [25]. Diagnoses recorded on
Table 2: Risk of hospitalization for ischemic heart disease in patients with unexplained chest/epigastric pain patients (UCEP). 
UCEP patients* 
(N = 386), n (%)
Population controls** 
(N = 3,793), n (%)
Crude relative 
risk
Adjusted relative 
risk‡
Ischemic heart disease: 
myocardial infarction, angina,
and/or heart failure
39 (11) 241 (6) 1.7 (1.2-2.4) 1.6 (1.1-2.2)
Time of diagnosis of ischemic heart disease after upper endoscopy
<1 year 5 (1.3) 24 (0.6) 2.1 (0.8–5.4) 1.9 (0.7–5.0)
1–2 years 5 (1.3) 19 (0.5) 2.7 (1.0–7.2) 2.5 (0.9–6.7)
3–4 years 8 (2.1) 57 (1.5) 1.5 (0.7–3.1) 1.4 (0.6–2.8)
≥ 5 years 21 (5.4) 141 (3.7) 1.6 (1.0–2.5) 1.5 (0.9–2.3)
Crude and adjusted relative risks and 95% confidence intervals for hospitalization for ischemic heart disease, overall, and by time since the index 
date in UCEP patients compared with population controls.
* Normal upper endoscopy and no discharge diagnoses of ischemic heart disease before study entry.
** No discharge diagnoses of ischemic heart disease before study entry.
‡ Adjusted for alcohol- and smoking related diseases, and Charlson comorbidity index: no comorbidity (Charlson Index 0), comorbidity level 1 
(Charlson Index 1–2) and comorbidity level 2 (Charlson Index > 2).
Kaplan-Meier curves for patients with unexplained chest/epi-gastric pain (UCEP) (N = 386) and population controls (N = 3,793)Figure 1
Kaplan-Meier curves for patients with unexplained 
chest/epigastric pain (UCEP) (N = 386) and popula-
tion controls (N = 3,793). --------- UCEP patients. ______ 
population controls.Page 5 of 9
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likelihood of misclassification, though most likely non-
differential. To reduce variation in definition of diagnoses
and symptoms, a single physician coded and entered the
information from the medical records into a research
database. Though some misclassification of UCEP cannot
be ruled out, it is unlikely to be related to the outcomes
measured.
Despite the limited level of clinical detail available in
administrative data, we were able to adjust for alcohol-
and smoking-related diseases and for comorbidity. How-
ever, adjusting for these potential confounders did not
change our relative estimates. The Charlson Index has
been shown to have high specificity, but its sensitivity is
diagnosis-dependent [27], so that residual confounding
by comorbidity cannot be ruled out. Further, since dis-
charge diagnoses are proxy measurements for alcohol
abuse and smoking, misclassification of these factors may
have also produced residual confounding.
The UCEP patients in our study may resemble patients
with upper FGIDs in characteristics such as functional
chest pain of presumed esophageal origin [often termed
non-cardiac chest pain (NCCP)], functional dyspepsia
(epigastric pain only), or the epigastric pain syndrome
[20,21]. In order to exclude patients with organic upper
gastrointestinal diseases, we restricted our study to
patients with a normal upper endoscopy and chest and/or
epigastric pain as the sole symptom. Therefore, patients
with reflux-like symptoms or dyspepsia-like symptoms
described in the medical record were excluded. Likewise,
we excluded UCEP patients who had received an IHD
diagnosis before enrollment in the study. However, it is
possible that some UCEP patients had undiagnosed IHD.
Exclusion of underlying IHD is very difficult, and, as has
been recently shown, even coronary angiography is not
guaranteed to rule out this condition [28]. It is also possi-
ble that normal endoscopy and absence of reflux-like
symptoms do not eliminate the possibility of GERD in
small proportion of UCEP patients [29]. However, even
the addition of pH monitoring data or documentation of
response to anti-reflux therapy would not suffice to
exclude GERD, because of the variable quality of such
information [29]. Finally, it could be argued that patients
with chest pain should be considered separately from
patients with pain in the epigastrium. However, a clear
differentiation of the two pain locations based on medical
records was not feasible. It is well known that pain from
viscera is often difficult to localize and that there is a
major overlap of symptoms of pain emanating from the
esophagus and related organs [1,30]. This has been also
demonstrated in experimental studies [1,30-32]. Hence,
the combination of pain from the chest and epigastrium
appears to be a valid approach to a common clinical prob-
lem.
Table 3: Mortality in patients with unexplained chest/epigastric pain (UCEP). 
UCEP patients* 
(N = 386), n (%)
Population controls** 
(N = 3,793), n (%)
Crude MRR Adjusted MRR†
Total deaths 62 (16) 508 (13) 1.2 (1.0–1.6) 1.1 (0.9–1.5)
Time to death after upper endoscopy
<1 year 10 (3) 40 (1) 2.7 (1.5–5.0) 2.4 (1.3–4.5)
1–2 years 14 (4) 83 (2) 1.9 (0.9–4.3) 1.7 (0.8–3.9)
3–4 years 6 (2) 93 (2) 1.0 (0.6–1.8) 0.9 (0.6–1.6)
≥ 5 years 32 (8) 292 (8) 1.0 (0.7–1.5) 0.9 (0.6–1.4)
Cause-specific deaths
Deaths from ischemic heart disease‡ 8 (2) 76 (2) 1.1 (0.5–2.2) 1.1 (0.5–2.2)
Deaths from arteriosclerosis 
(not ischemic heart disease, not stroke)
4 (1) 51 (1) 0.8 (0.3–2.1) 0.7 (0.3–2.1)
Deaths from pneumonia 12 (3) 41 (1) 2.8 (1.5–5.4) 2.7 (1.4–5.2)
Deaths from stroke 4 (1) 34 (1) 1.1 (0.4–3.1) 1.1 (0.4–3.2)
Deaths from lung cancer 5 (1) 27 (1) 1.9 (0.7–4.9) 1.7 (0.6–4.4)
Deaths from alcohol dependence§ 3 (1) 5 (0.1) 3.4 (0.7–16.8) 1.5 (0.3–8.2)
Deaths from chronic obstructive pulmonary disease¶ 3 (1) 38 (1) 0.7 (0.2–2.4) 0.8 (0.2–2.5)
Crude and adjusted mortality rate ratios (MRR) and 95% confidence intervals for patients with unexplained chest/epigastric pain (UCEP) compared 
with population controls, overall, time-dependent, and by cause of death.
* Normal upper endoscopy and no discharge diagnoses of ischemic heart disease before study entry.
** No discharge diagnoses of ischemic heart disease before study entry.
† Adjusted for alcohol- and smoking-related diseases, and Charlson comorbidity Index: no comorbidity (Charlson Index 0), comorbidity level 1 
(Charlson. Index 1–2) and comorbidity level 2 (Charlson Index > 2).
‡ Myocardial infarction, angina, and/or heart failure.
§ Not adjusted for alcohol-related diseases.
¶ Not adjusted for smoking-related disease.Page 6 of 9
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of undiagnosed IHD at the time of upper endoscopy.
However, the risk remained elevated more than 5 years
after the procedure. This is a strong indication that UCEP
is an early marker of IHD, a finding that until now has not
been reported.
The finding of increased cardiac and overall mortality
among UCEP patients conforms with a previous cohort
study among NCCP patients [14] and another among
patients with non-ulcer dyspepsia (subgroup of FGID)
[16], both using comparison groups drawn from the gen-
eral population. In contrast, our results disagree with
those reported in two other cohort studies among NCCP
patients, both of which used asymptomatic persons as a
control group [13,15]. All four cohort studies have impor-
tant limitations that were avoided in our study. Three
studies did not include results of upper endoscopy exam-
inations [13-15], which could lead to inclusion of a large
proportion of patients with a known underlying gastroin-
testinal cause of pain (up to 30% of NCCP patients [5]).
In addition, the study of patients with non-ulcer dyspep-
sia [16] included patients with 'discomfort' and reflux-like
symptoms, which are explicitly excluded from the FGIDs
in the recently defined Rome III criteria in order to avoid
overlap with organic disease (mainly GERD) [21]. Two
studies were restricted to men aged 40–59 years [13,15].
One study examined a combined outcome (major IHD
events [fatal and non-fatal]), complicating the interpreta-
tion of the result [13]. Finally, none of the studies esti-
mated short- or long-term risks, and thus could not detect
potential trends in risk.
The short-term increase in all-cause mortality among
UCEP patients found in our study might be explained by
the presence of severe underlying disease undiagnosed at
the time of upper endoscopy, which could raise the risk of
death shortly after the procedure. However, our data may
indicate a truly increased risk of death from alcohol
dependence, pneumonia (>31 days after procedure), and
lung cancer, despite the low statistical precision of our rel-
ative mortality estimates. Pneumonia has been reported
as a complication of upper endoscopy predominantly
within 7 days after the procedure [33]. Therefore the risk
increase observed in this study cannot be explained by the
endoscopy procedure itself.
No obvious pathophysiological mechanism can explain
the increase in cause-specific deaths found in our study.
The findings could be due to chance or to unmeasured
confounding.
Conclusion
Our main study findings suggest that UCEP patients have
substantially increased risk of hospitalization for IHD and
all-cause mortality during 10-years of follow-up.
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Appendix 1
Discharge diagnosis according to the International 
Classification of Diseases (ICD)
Ischemic heart disease (IHD):
Myocardial infarction: ICD-8 code 410 and ICD-10 codes
I21-23.
Angina: ICD-8 codes 411.09, 411.99 and ICD-10 code
I20.
Heart failure: ICD-8 codes 402.99, 403.99, 425.99,
427.09, 427.19 and ICD-10 codes I13.0, I25.5, I42.0,
I42.6-9, I50.0, I50.1, I50.9.
Pneumonia: ICD-8 code 486 and ICD-10 codes J18.0,
J18.9.
Arteriosclerosis: ICD-8 code 412.9 and ICD-10 codes
I25.1, I70.9.
Stroke: ICD-10 codes I61.9, I64.9, I69.4.
Lung cancer: ICD-8 code 162.1 and ICD-10 code C34.9.
Alcohol dependence: ICD-10 code F10.2.
Chronic obstructive pulmonary disease: ICD-10 codes
J42.9, J43.9, J44.8, J44.9, I27.9.
Alcohol-related diseases: ICD-8 codes 303.09, 303.19,
303.20, 303.28, 303.29, 303.90, 303.99, 979, 980, 570.0,
570.9, 571, 571.09, 571.10, 573.00, 573.01, 577.10 andPage 7 of 9
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R78.0, T51.
Smoking-related diseases: ICD-8 codes 491, 492 and ICD-
10 codes J40-44, J98.2, J98.3.
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